These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15996933)

  • 1. Targeting mutated protein tyrosine kinases and their signaling pathways in hematologic malignancies.
    Chalandon Y; Schwaller J
    Haematologica; 2005 Jul; 90(7):949-68. PubMed ID: 15996933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
    Walz C; Sattler M
    Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases.
    Chase A; Cross NC
    Clin Sci (Lond); 2006 Oct; 111(4):233-49. PubMed ID: 16961463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib.
    Ernst T; Erben P; Müller MC; Paschka P; Schenk T; Hoffmann J; Kreil S; La Rosée P; Hehlmann R; Hochhaus A
    Haematologica; 2008 Feb; 93(2):186-92. PubMed ID: 18223278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular genetics of human leukemias: new insights into therapy.
    Gilliland DG
    Semin Hematol; 2002 Oct; 39(4 Suppl 3):6-11. PubMed ID: 12447846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roots of imatinib resistance: a question of self-renewal?
    Burchert A
    Drug Resist Updat; 2007; 10(4-5):152-61. PubMed ID: 17683977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
    Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
    Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
    Soverini S; Colarossi S; Gnani A; Rosti G; Castagnetti F; Poerio A; Iacobucci I; Amabile M; Abruzzese E; Orlandi E; Radaelli F; Ciccone F; Tiribelli M; di Lorenzo R; Caracciolo C; Izzo B; Pane F; Saglio G; Baccarani M; Martinelli G;
    Clin Cancer Res; 2006 Dec; 12(24):7374-9. PubMed ID: 17189410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Important therapeutic targets in chronic myelogenous leukemia.
    Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
    Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience].
    Nausová J; Priwitzerová M; Jarosová M; Indrák K; Faber E; Divoký V
    Cas Lek Cesk; 2006; 145(5):377-82. PubMed ID: 16755775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advancing the treatment of hematologic malignancies through the development of targeted interventions.
    Tallman MS
    Semin Hematol; 2002 Oct; 39(4 Suppl 3):1-5. PubMed ID: 12447845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to targeted therapy in chronic myelogenous leukemia.
    Hochhaus A; Erben P; Ernst T; Mueller MC
    Semin Hematol; 2007 Jan; 44(1 Suppl 1):S15-24. PubMed ID: 17292737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression analysis of BCR/ABL1-dependent transcriptional response reveals enrichment for genes involved in negative feedback regulation.
    Håkansson P; Nilsson B; Andersson A; Lassen C; Gullberg U; Fioretos T
    Genes Chromosomes Cancer; 2008 Apr; 47(4):267-75. PubMed ID: 18181176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapy in chronic myeloid leukemia.
    Jabbour E; Cortes JE; Ghanem H; O'Brien S; Kantarjian HM
    Expert Rev Anticancer Ther; 2008 Jan; 8(1):99-110. PubMed ID: 18095887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The biology of chronic myelogenous leukemia: implications for imatinib therapy.
    Alvarez RH; Kantarjian H; Cortes JE
    Semin Hematol; 2007 Jan; 44(1 Suppl 1):S4-14. PubMed ID: 17292736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute monocytic leukemia with coexpression of minor BCR-ABL1 and PICALM-MLLT10 fusion genes along with overexpression of HOXA9.
    Sindt A; Deau B; Brahim W; Staal A; Visanica S; Villarese P; Rault JP; Macintyre E; Delabesse E
    Genes Chromosomes Cancer; 2006 Jun; 45(6):575-82. PubMed ID: 16518848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rottlerin synergistically enhances imatinib-induced apoptosis of BCR/ABL-expressing cells through its mitochondrial uncoupling effect independent of protein kinase C-delta.
    Kurosu T; Tsuji K; Kida A; Koyama T; Yamamoto M; Miura O
    Oncogene; 2007 May; 26(21):2975-87. PubMed ID: 17130834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BCR-ABL in chronic myelogenous leukemia--how does it work?
    Goldman JM; Melo JV
    Acta Haematol; 2008; 119(4):212-7. PubMed ID: 18566539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Abnormal activation of tyrosine kinases and its role in the pathogenesis of hematological malignancies - review].
    Sun XM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Jun; 15(3):657-61. PubMed ID: 17605888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mitogen-activated protein kinase signaling module as a therapeutic target in hematologic malignancies.
    Milella M; Kornblau SM; Andreeff M
    Rev Clin Exp Hematol; 2003 Jun; 7(2):160-90. PubMed ID: 14763161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.